Home MarketSun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. Stock Info: As on 2017-11-17 15:58:20

Nse

392.10

0.70(0.18%)
Change%
52 Week Range
272.00
30.00
446.00
30.00
Open395.00
Day's Range313.12 - 469.68
Value Traded (in ₹ Cr.) 10.46

Bse

391.85

0.00(0.00%)
Change %
52 Week Range
273.00
29.00
445.00
30.00
Open396.00
Day's Range313.48 - 470.22
Value Traded (in ₹ Cr.) 3.08

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 165,255,715.00 66.93%
Mutual Funds/UTI 5,203,749.00 2.11%
FII 15,360,697.00 6.22%
Employee 0.00 0.00%
Public 36,286,832.00 14.70%
Government 0.00 0.00%
Others 24,607,940.00 9.97%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 42.26
Basic EPS (Rs.) -2.96
Cash EPS -2.64
BVPerShare Excl 1.26
Operating Revenue 6.81
PBDITPerShare -2.55
Dividend 0.00
NPPerShare -2.96
Current Ratio 0.53
Quick Ratio 0.53
PriceToBV 227.93
Earnings -0.01
PBDIT Margin -37.36
PBT Margin -43.39
NP Margin -43.39
Return On Assets -43.02
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 164.22
Total Expenses 234.21
EBITDA -60.26
PBT -69.99
PAT -69.99
Net Income -69.99
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 77.59
Total Expenses 126.24
EBITDA -52.52
PBT -50.60
PAT -50.60
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.20
Net block 70.83
Total Assets 162.66
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.21
Net block 70.83
Total Assets 162.66
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

400.95 397.2 0.94
403.65437.25

Banaras Beads Ltd.

60.8 60.55 0.41
59.663.5

Binani Industries Ltd.

88.4 89.1 -0.79
83.294.35

Career Point Ltd.

130.2 129.85 0.27
127.1139.75

Dredging Corporation Of India Ltd.

704.75 708.45 -0.52
680.55759

Future Consumer Ltd.

58.15 59 -1.44
58.862.95

Gateway Distriparks Ltd.

258.25 251.9 2.52
233269.25
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

400.75 397 0.94
404.35437

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

28 28.2 -0.71
26.828.2

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

60.5 60.55 -0.08
59.464.8

Binani Industries Ltd.

88 88.85 -0.96
82.8593.9

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 44.21
Cash from investing activities 13.08
Cash from financing activities -50.55
Net change in cash 6.63

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Axis Focused 25 Fund 1.93%
Axis Long Term Equity Fund 0.27%
UTI Mid Cap Fund 0.78%
UTI Equity Fund 0.45%
DSP BlackRock Micro-Cap Fund 0.31%
UTI Opportunities Fund 0.44%

PVR to acquire minority stake in US-based theatre firm iPic

PVR said it will acquire a minority stake in US-based luxury restaurant and theatre company iPic Gold Class Entertainment LLC (iPic) for an undisclosed sum, a move that would give PVR exposure in the cinema exhibition market of the US, reported PTI. iPic owns and operates 16 luxury theatres and 121 screens across 10 states in the United States. The Board of Directors approved the proposed investment and strategic partnership between PVR and iPic, PVR Ltd said in a regulatory filing. The completion of investment is subject to relevant corporate and regulatory approvals. Besides, iPic has agreed to appoint PVR Chairman and Managing Director Ajay Bijli to its board of directors after its planned initial public offering that it had announced earlier.

17-11-2017 10:39

ArcelorMittal, Tata Steel evince interest in Bhushan Steel

ArcelorMittal and domestic industry major Tata Steel have evinced interest in Bhushan Steel which is undergoing insolvency proceedings, reported PTI. The development has come at a time when the debt-laden firm, which was referred to NCLT by the RBI under the Insolvency and Bankruptcy Code, has reported narrowing down of its standalone net loss to Rs 467.37 crore during the September quarter from Rs 980.22 crore in the same period a year ago. During the July-September 2017, total income of Bhushan Steel rose 43 per cent to Rs 4,325.60 crore from Rs 3,025.79 crore during the same period a year ago, the company said in a BSE filing. Yes! ArcelorMittal is interested in Bhushan Steel, said a person in the know of the matter and refused to elaborate further. When contacted, a Tata Steel company official said, The company keeps on looking at such opportunities. Last month, Tata Steel and ArcelorMittal had submitted expression of interest (EoI) to acquire debt-laden Essar Steel -- another stressed company undergoing the insolvency proceedings at the National Company Law Tribunal (NCLT). Essar Steel India Ltd, an integrated steel producer with an installed capacity of 10 million tonne per annum (MTPA) is undergoing Corporate Insolvency Resolution Process (CIRP) under the provisions of Insolvency and Bankruptcy Code. According to the information on Bhushan Steel Ltd website, the company is the 3rd largest secondary steel producer in the country with an existing steel production capacity of 5.6 million ton per annum. Both Tata Steel and ArcelorMittal see the proceedings as an opportunity as the two companies are looking to expand their operations in the country.

17-11-2017 10:28

Jaiprakash Associates approves 'cashless exchange' of bonds

Debt-ridden Jaiprakash Associates' finance committee has approved cashless exchange of existing convertible bonds worth USD 150 million due in 2017 with those maturing in 2020-21, reported PTI. Earlier this month, the RBI had approved the proposal. In a BSE filing, Jaiprakash Associates said that the finance committee in its meeting held today has deemed to have opened and closed the cashless exchange of the existing bonds with the bonds... In June, Jaiprakash Associates had said that bondholders agreed to exchange outstanding existing foreign currency convertible bonds (FCCBs) worth USD 150 million. The bonds were issued in September 2012 with maturity in 2017 and a coupon rate of 5.75 per cent. As per the proposal, the bondholders agreed to exchange their current bonds with FCCBs worth USD 38.64 million bearing the same coupon rate with maturity in 2021 and amortising bonds worth USD 81.69 million with coupon rate of 4.76 per cent and maturity in 2020. According to the regulatory filing, Jaiprakash Associates will issue 1,10,400 'Series A' bonds having principle value of USD 350 each carrying a coupon rate of 5.75 per cent per annum with maturity on September 30, 2021. It will also issue 1,10,400 'Series B' bonds having principle value of USD 740 each at a coupon rate of 4.76 per cent per annum and maturity date of September 30, 2020. That apart, the company will pay USD 27.6 million upfront. The finance committee has authorised execution of all transaction document and closing of the transaction would take place on restructuring effective date, which is expected to take place on or before November 30, 2017, on which date the allotment of the bonds and issuance of global certificates would be made, the filing said. Both series of the bonds would be listed on Singapore Stock Exchange Securities Trading Ltd. Jaiprakash Associates, which is the flagship company of the Jaypee group, is selling its assets to repay debt. It is a diversified infrastructure company engaged in segments like engineering, construction and real estate development, cement manufacturing, hospitality and sports management. Jaypee Group firm Jaypee Infratech has been taken over by a National Company Law Tribunal (NCLT)-appointed IRP (Insolvency Resolution Professional) for recovery of bad loans. The group is facing huge protest from home buyers due to significant delays in delivery of projects.

17-11-2017 10:26

Tata Power allots debentures worth Rs 1500 cr

Tata Power has raised Rs 1,500 crore through issuance of unsecured, redeemable and non- convertible debentures worth Rs 1,500 crore on private placement basis, reported PTI. Company alloted unsecured, non-cumulative, redeemable, taxable, listed, rated non-convertible debentures of Rs 1,500 crore on November 16, 2017 on private placement basis, Tata Power said in a BSE filing. According to the statement, the tenure of these 15,000 debentures is seven years.

17-11-2017 10:21

Cipla gets final nod for Generic Pulmicort Respules

Drug maker Cipla on Friday said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide InhalationSuspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA) to market a generic version of Astrazeneca’s Pulmicort Respules. “Cipla’s Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age,” the company said in a filing to the Bombay Stock Exchange. The product is available for shipping immediately, it said. Pulmicort Respules and generic equivalents had US sales of approximately USD 825 Million for the 12-month period ending September 2017, as reported by IMS Health.

17-11-2017 09:09

Sun Pharma Advanced Research posts Q2 net loss of Rs 62.57 cr

The company reported standalone net loss during the quarter stood at Rs 62.57 crore compared to net profit of Rs 14.74 crore in the previous year quarter. Net revenue of the company declined substantially by 83.81 per cent at Rs 15.36 crore in July-September quarter of this fiscal as against Rs 94.89 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 5.92 per cent to Rs 76.82 crore from Rs 81.65 crore in year ago period. Other Income dipped by 75.50 per cent at Rs 0.99 crore versus (Sep'16 Rs 4.04 crore). Operating Profit slipped by 564.20 per cent to Rs -61.46 crore as against Rs 13.24 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 2968.32 per cent in September quarter. Interest declined by 95.35 per cent y-o-y to Rs 0.02 crore

28-Oct-2017 11:30 AM

Sun Pharma Advanced - Financial Result Updates

Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

27-Oct-2017 07:15 PM

Sun Pharma Advanced - Outcome of Board Meeting

Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Outcome of Board Meeting held on October 27, 2017.The Board of Directors of the Company at their meeting held from 05:00 pm to 07:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and six months ended 30th September 2017 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I.

27-Oct-2017 07:13 PM

Sun Pharma Advanced - Outcome of Board Meeting

The Board of Directors of the Company at their meeting held from 05:00 pm to 07:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and six months ended 30th September 2017 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I.

This is for your information and record.

27-Oct-2017 07:09 PM

Sun Pharma Advanced - PCS Certificate Under Regulation 40(9) For The Half Year Ended 30Th September 2017

As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 18th April 2016 issued by Mr. Chintan Goswami, M/S. C. J Goswami & Associates, Practicing Company Secretaries, for the half year ended 30th September 2017.

This is for your information and records.

14-Oct-2017 06:25 PM

Sun Pharma Advanced - Outcome of Board Meeting

The Board of Directors of the Company at their meeting held from 05:00 pm to 07:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and six months ended 30th September 2017 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I.

This is for your information and record.

27-Oct-2017 07:09 PM

Sun Pharma Advanced - PCS Certificate Under Regulation 40(9) For The Half Year Ended 30Th September 2017

As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 18th April 2016 issued by Mr. Chintan Goswami, M/S. C. J Goswami & Associates, Practicing Company Secretaries, for the half year ended 30th September 2017.

This is for your information and records.

14-Oct-2017 06:25 PM

Sun Pharma Advanced - Shareholding for the Period Ended September 30, 2017

Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017.

12-Oct-2017 09:52 AM

Corporate Details

About Management

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

Registered Office

17-B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East)

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.